Synthesis and Bioevaluation of Novel Imatinib Base Derivatives via 1,1′-Carbonyldiimidazole Catalyst

Patoliya, M. J.; Kharadi, G. J.

doi:https://doi.org/10.1155/2013/915381

Journal of Chemistry

On this page

Abstract Introduction Experimental Discussion Conclusion Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2013 | Article ID 915381 | https://doi.org/10.1155/2013/915381

Synthesis and Bioevaluation of Novel Imatinib Base Derivatives via 1,1′-Carbonyldiimidazole Catalyst

M. J. Patoliya¹and G. J. Kharadi²

Academic Editor: Olga Gortzi

Received27 Jun 2013

Revised19 Sept 2013

Accepted21 Sept 2013

Published07 Nov 2013

Abstract

A series of eleven compounds were synthesized from 6-methyl-N′-(4-(pyridine-3-yl)pyrimidin-2-yl)benzene-1,3-diamine with various substituted carboxylic acid under solvent-free conditions using 1,1′-carbonyldiimidazole (CDI) as a catalyst. The yields of compounds are more than 72%. All the compounds were characterized by physical, spectroscopic, and elemental analysis. Compound 8b exhibited good inhibition towards antimicrobial activity compared to the other compounds.

1. Introduction

Imatinib mesylates (Gleevec, N-(4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamidemethanesulfonate, STI571) base is known as an inhibitor of tyrosine kinases and is indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs) [1–8]. Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Imatinib is a 2-phenylamino-pyrimidine derivative. It was developed by Novartis Pharma AG, Basel, Switzerland, and licensed for treatment of patients with chronic myeloid leukaemia. The 2-phenylaminopyrimidine (PAP) derivative, STI-571, (4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridine-3-yl-pyrimidin-2ylamino)phenyl]benzamidemesylate, imatinib mesylate, Gleevec) is a potent and relative selective Bcr-Abl tyrosine kinase inhibitor that has shown potent efficacy in CML patients in chronic phase [9, 10]. Although newly diagnosed patients with chronic phase disease achieve durable responses to STI-571 therapy, relapse and resistance are frequently observed in patients with advanced disease [11, 12]. Mutations in the kinase domain of Bcr-Abl have been found to be one of the main reasons of resistance to STI-571 [13].

We aimed our research work towards developing an industrially feasible and cost-effective process for the preparation of imatinib and its analogues. An improved method for the preparation of imatinib is described in this paper (Figure 1).

2. Experimental

2.1. Materials and Instrumentation

All reagents were of analytical reagent grade and were used without further purification. Solvents used were purified by standard procedures before use. substituted carboxylic acid was purchased from Aldrich. Melting points were determined in open capillaries on a Veego (model VMP-D) electronic apparatus and are uncorrected. Thin-layer chromatography was performed on microscope slides (2 cm · 97.5 cm) coated with silica gel G for monitoring of the reactions as well as to establish the identity and purity of the compounds. Ethyl acetate-cyclohexane was used as mobile phase and spots were visualized under UV irradiation. Elemental analysis (C, H, and N) was performed by Perkin-Elmer, USA, 2400-II CHN analyzer. FTIR spectra (4,000–400 cm⁻¹) were recorded on a Shimadzu 8400-S spectrophotometer using KBr disks. Nuclear magnetic resonance spectra were recorded on a Varian 400 MHz spectrometer using DMF as a solvent and TMS as internal reference (chemical shifts in ppm).

2.2. General Procedure of Compound (8a–k)

A mixture of 6-methyl-N′(4-(pyridine-3-yl)pyrimidin-2-yl)benzene-1,3-diamine (35 mmol), substituted carboxylic acid (55 mmol) (Table 1), 1,1′-Carbonyldiimidazole (55 mmol) in N,N-Dimethylformamide (5 mL) were taken in round bottom flask. The reaction mixture was heated up to 50–60°C and stirred for 8–10 hours on completion of reaction monitored by TLC (ethyl acetate : cyclohexane = 1 : 1); the reaction mixture was cooled to room temperature, and reaction mass was dumped into water. The solid separated was filtered and washed with water. Furthermore, the solid was suspended in Isopropylalcohol and stirred for 30 minute and filtered to get a pure product [14, 15].

2.2.1. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)benzamide 8a

Off white, Yield 82%; m.p. 170°C; ¹H NMR (400 MHz, DMF), 7.63(m, 2H), 8.03(d, 2H), 7.70(t, 1H), 9.15(Sec. –NH), 6.83(m, 1H), 6.92(m, 1H), 6.96(m, 1H), 4.0(Ar–NH), 2.12(s, 3H), 8.60(d, 1H), 7.24(d, 1H), 8.42(d, 1H), 9.24(s, 1H), 7.57(t, 1H), 8.70(m, 1H); ¹³C NMR (100 MHz, DMF), C = 168.6, 157.9, 142.2, 133.7, 133.0, 124.6, 134.2, 164.7, CH = 157.6, 147.9, 147.5, 103.3, 107.9, 111.5, 130.0, 127.5, 124.0, 134.0, 127.5, 128.8, 128.8, 132.1 CH₃ = 17.6; FTIR (KBr): 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=C·C=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 382 (M+1) Anal. Calc. for C₂₃H₁₉N₅O (381.43): C, 72.42; H, 5.02; N, 18.36 Found: C, 72.36; H, 5.00; N, 18.16.

2.2.2. 2-Hydroxy-N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)benzamide 8b

Off white, Yield 80%; m.p. 178°C; ¹H NMR (400 MHz, DMF), 7.19(t, 1H), 7.53(t, 1H), 7.86(d, 1H), 6.95(d, 1H), 5.35(–OH), 9.15(Sec. –NH), 4.0(Ar–NH), 2.12(s, 3H), 8.60(d, 1H), 7.24(m, 1H), 8.42(d, 1H), 9.24(s, 1H), 7.57(t, 1H), 8.70(d, 1H), 6.83(m, 1H), 6.92(m, 1H), 6.96(m, 1H); ¹³C NMR (100 MHz, DMF), C = 159.4, 168.6, 157.9, 142.2, 133.7, 133.0, 119.8, 124.6, 164.7, CH = 157.6, 147.9, 147.5, 103.3, 107.9, 111.5, 130.0, 117.8, 124.0, 134.0, 128.9, 133.5, 121.4, CH3 = 17.6; FTIR (KBr): 3446 cm⁻¹ (Aromatic O–H Stretching), 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 398.23 (M+1) Anal. Calc. for C₂₃H₁₉N₅O₂ (397.43): C, 69.51; H, 4.82; N, 17.62 Found: C, 69.49; H, 4.62; N, 17.59.

2.2.3. 2-Hydroxy-N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-2-phenylacetamide 8c

Off white, Yield 76%; m.p. 180°C; ¹H NMR (400 MHz, DMF), 3.65(–OH), 4.0(Ar–NH), 7.23(Sec. NH), 7.36(d, 2H), 7.38(d, 2H), 7.38(d, 1H), 5.45(s, 1H), 6.92(d, 1H), 6.83(s, 1H), 6.96(d, 1H), 2.12(s, 3H), 8.60(d, 1H), 7.24(d, 1H), 8.42(d, 1H), 7.57(m, 1H), 8.7(d, 1H), 9.24(s, 1H); ¹³C NMR (100 MHz, DMF), C = 168.6, 157.9, 142.2, 136.3, 133.0, 124.6, 139.1, 168.2, CH = 157.6, 147.9, 147.5, 103.3, 107.9, 111.5, 130, 129.6, 124, 134, 129.6, 129.2, 129.2, 127.6, 74, CH₃ = 17.6; FTIR (KBr): 3613 cm⁻¹ (Free C–OH Stretching), 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1403 cm⁻¹ (O–H Banding), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N stretching), 1091 cm⁻¹ (C–O Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 412 (M+1) Anal. Calc. for C₂₄H₂₁N₅O₂ (411.46): C, 70.06; H, 5.14; N, 17.02 Found: C, 70.02; H, 5.08; N, 17.00.

2.2.4. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)thiophene-2-carboxamide 8d

Creemish, yield 85%; m.p. 200°C; ¹H NMR (400 MHz, DMF), 7.27(m, 1H), 8.30(d, 1H), 8.14(d, 1H), 4.0(Ar–NH), 9.15(Sec. –NH), 6.92(d, 1H), 6.83(s, 1H), 6.96(d, 1H), 2.12(s, 3H), 8.6(d, 1H), 7.24(d, 1H), 8.42(m, 1H), 7.57(t, 1H), 8.70(d, 1H), 9.24(s, 1H); ¹³C NMR (100 MHz, DMF), C = 139.4, 168.6, 157.9, 142.2, 133.7, 133, 124.6, 161.8, CH = 130.3, 131.9, 129, 157.6, 147.9, 147.6, 103.3, 107.9, 111.5, 130, 124, 134, CH₃ = 17.6; FTIR (KBr): 2577 cm⁻¹ (S–H Stretching), 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1922 cm⁻¹ (five member C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C-H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 386.64 (M+1) Anal. Calc. for C₂₁H₁₇N₅OS (387.46): C, 65.10; H, 4.42; N, 18.08 Found: C, 65.02; H, 4.14; N, 18.01.

2.2.5. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)pyrazine-2-carboxamide 8e

Creemish, yield 72%; m.p. 220°C; ¹H NMR (400 MHz, DMF), 9.03(d, 1H), 8.89(d, 1H), 9.96(s, 1H), 4.0(Ar–NH), 9.15(Sec.–NH), 6.92(d, 1H), 6.83(s, 1H), 6.96(d, 1H), 2.12(s, 3H), 8.6(d, 1H), 7.24(d, 1H), 8.42(m, 1H), 7.57(t, 1H), 8.70(d, 1H), 9.24(s, 1H); ¹³C NMR (100 MHz, DMF), C = 168.6, 137.9, 145.0, 142.2, 133.7, 133.0, 124.6, 162.6, CH = 146.0, 144.6, 157.6, 147.9, 144.7, 147.5, 103.3, 107.9, 1211.5, 130.0, 124.0, 134.0, CH₃ = 17.6; FTIR (KBr): 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1499 cm⁻¹ (C=C Stretching), 1461 cm⁻¹ (Aromatic C=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 384.35 (M+2) Anal. Calc. for C₂₁H₁₇N₇O (383.41): C, 65.79; H, 4.47; N, 25.57 Found: C, 65.69; H, 4.38; N, 25.38.

2.2.6. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)pyrimidine-2-carboxamide 8f

Creemish, yield 75%; m.p. 250°C; ¹H NMR (400 MHz, DMF), 2.13(s, 3H), 6.74(d, 1H), 7.56(d, 1H), 8.74(d, 1H), 8.82(d, 1H), 8.93(d, 1H), 8.34(d, 1H), 8.24(d, 1H), 7.19(d, 1H), 6.93(d, 1H), 6.50(d, 1H), 9.17(d, 1H), 7.2(d, 1H), 4.0(Ar–NH), 9.15(Sec. –NH); ¹³C NMR (100 MHz, DMF), C = 168.6, 158.1, 157.9, 142.2, 133.7, 133.0, 124.6, 157.9, CH = 157.6, 157.2, 147.9, 147.5, 157.2, 103.3, 123.6, 107.9, 111.5, 130.0, 124.0, 134.0, CH₃ = 17.6; FTIR (KBr): 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1461 cm⁻¹ (Aromatic C=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 383 (M+1) Anal. Calc. for C₂₁H₁₇N₇O (383.41): C, 65.79; H, 4.47; N, 25.57, Found: C, 65.60; H, 4.40; N, 25.42.

2.2.7. 2-Methyl-N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)benzamide 8g

Off white, yield 80%; m.p. 180°C; ¹H NMR (400 MHz, DMF), 2.13(s, 3H), 2.20(s, 3H) 7.61(d, 1H), 7.74(d, 1H), 7.45(d, 1H), 7.72(d, 1H), 8.88(d, 1H), 7.19(d, 1H), 7.93(d, 1H), 7.14(d, 1H), 6.89(d, 1H), 6.45(d, 1H), 8.79(d, 1H), 8.97(d, 1H), 7.24(d, 1H), 4.0(Ar–NH), 9.15(Sec. –NH); ¹³C NMR (100 MHz, DMF), C = 168.6, 157.9, 142.2, 133.7, 133.0, 136.5, 132.7, 124.6, 160.3, CH = 157.6, 147.9, 147.5, 107.9, 103.3, 111.5, 130.0, 124.0, 134.0, 127.4, 131.5, 128.7, 132, CH₃ = 18.1, 17.6; FTIR (KBr): 2931 cm⁻¹ (Alkane C–H Stretching), 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=C·C=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 396 (M+1) Anal. Calc. for C₂₄H₂₁N₅O (395.46): C, 72.89; H, 5.35; N, 17.71 Found: C, 72.77; H, 5.26; N, 17.66.

2.2.8. 4-Amino-N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)benzamide 8h

Off white, yield 77%; m.p. 210°C; ¹H NMR (400 MHz, DMF), 2.19(s, 3H), 7.36(d, 1H), 7.86(d, 1H), 8.86(d, 1H), 7.92(d, 1H), 7.08(d, 1H), 7.08(d, 1H), 6.92(d, 1H), 6.63(d, 1H), 7.47(d, 1H), 7.47(d, 1H), 8.79(d, 1H), 8.97(d, 1H), 7.23(d, 1H), 9.15(Sec. –NH), 6.27 (Ar–NH₂), 4.0(Ar–NH); ¹³C NMR (100 MHz, DMF), C = 168.6, 157.9, 142.2, 133.7, 151.8, 133.0, 124.6, 124.2, 164.7, CH = 157.6, 147.9, 147.5, 103.3, 107.9, 111.5, 114.3, 130.0, 130.2, 124.0, 114.3, 134.0, 130.2, CH₃ = 17.6; FTIR (KBr): 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1639 cm⁻¹ (primary amine N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1189 cm⁻¹ (C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 398 (M+1) Anal. Calc. for C₂₃H₂₀N₆O (396.44): C, 69.68; H, 5.08; N, 21.20 Found: C, 69.61; H, 5.04; N, 21.16.

2.2.9. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-1h-imidazole-5-carboxamide 8i

Creemish, yield 79%; m.p. 215°C; ¹H NMR (400 MHz, DMF), 2.13(s, 3H), 7.42(d, 1H), 8.84(d, 1H), 8.31(d, 1H), 8.16(d, 1H), 8.16(d, 1H), 7.19(d, 1H), 6.98(d, 1H), 6.48(d, 1H), 9.17(d, 1H), 7.68(d, 1H), 7.18(d, 1H), 4.0(Ar–NH), 9.15(Sec. –NH), 13.0(Imidazole –NH); ¹³C NMR (100 MHz, DMF), C = 136.7, 168.6, 157.9, 142.2, 133.7, 133.0, 124.6, 162.6, CH = 145.0, 133.6, 157.6, 147.9, 147.5, 103.3, 107.9, 111.5, 130.0, 124.0, 134.0, CH₃ = 17.6; FTIR (KBr): 3246 cm⁻¹ (Secondary amine N–H Stretching), 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1554 cm⁻¹ (Aromatic C–N Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 790 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 372.76 (M+1) Anal. Calc. for C₂₀H₁₇N₇O (371.40): C, 64.68; H, 4.61; N, 26.40 Found: C, 64.62; H, 4.59; N, 26.26.

2.2.10. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-3-nitrobenzamide 8j

Off white, yield 82%; m.p. 230°C; ¹H NMR (400 MHz, DMF), 2.13(s, 3H), 7.56(d, 1H), 7.98(d, 1H), 8.71(d, 1H), 8.34(d, 1H), 8.08(d, 1H), 8.16(d, 1H), 7.88(d, 1H), 6.98(d, 1H), 7.15(d, 1H), 6.48(d, 1H), 9.17(d, 1H), 8.82(d, 1H), 7.18(d, 1H), 4.0(Ar–NH), 9.15(Sec. –NH); ¹³C NMR (100 MHz, DMF), C = 168.6, 157.9, 148.0, 142.2, 133.7, 133.0, 124.6, 135.1, 164.7, CH = 157.6, 147.9, 147.5, 103.3, 107.9, 123.3, 111.5, 130.0, 133.6, 124.0, 127.3, 134.0, 129.7, CH₃ = 17.6; FTIR (KBr): 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1521 cm⁻¹ (Nitro Compound N–O stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 863 cm⁻¹ (1,3-disubstituate C–H Stretching), 794 cm⁻¹ (1,4-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 428 (M+1) Anal. Calc. for C₂₃H₁₈N₆O₃ (426.43): C, 64.78; H, 4.25; N, 19.71 Found: C, 64.60; H, 4.21; N, 19.48.

2.2.11. N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-nitrobenzamide 8k

Creemish, yield 81%; m.p. 233°C; ¹H NMR (400 MHz, DMF), 2.13(s, 3H), 7.42(d, 1H), 8.63(d, 1H), 8.31(d, 1H), 8.15(d, 1H), 7.01(d, 1H), 7.15(d, 1H), 6.48(d, 1H), 8.12(d, 1H), 8.12(d, 1H), 8.14(d, 1H), 8.14(d, 1H), 7.17(d, 1H), 7.19(d, 1H), 4.0(Ar–NH), 9.15(Sec. –NH); ¹³C NMR (100 MHz, DMF), C = 168.6, 157.9, 151.3, 142.2, 133.7, 133.0, 124.6, 136.8, 164.7, CH = 157.6, 147.9, 147.5, 103.3, 107.9, 124.0, 111.5, 130.0, 129.6, 124.0, 124.0, 134.0, 129.6, CH₃ = 17.6; FTIR (KBr): 2136 cm⁻¹ (N=C–N Stretching), 1724.2 cm⁻¹ (Aromatic C–H Stretching), 1677 cm⁻¹ (C=O tert. amide), 1599 cm⁻¹ (N–H Stretching), 1515 cm⁻¹ (C=CC=N Stretching), 1305 cm⁻¹ (Aromatic C–N Stretching), 1176.1 cm⁻¹ (C–N Stretching), 783 cm⁻¹ (1,4-disubstituate C–H Stretching), 764 cm⁻¹ (1,2-disubstituate C–H Stretching), 713 cm⁻¹ (Aromatic C–H out of plane); ESI/MS m/z 427 (M+1) Anal. Calc. for C₂₃H₁₈N₆O₃ (426.43): C, 64.78; H, 4.25; N, 19.71 Found: C, 64.70; H, 4.13; N, 19.70.

2.3. Antibacterial Activity

Antibacterial activity of the synthesized compounds was determined against Gram-positive bacteria (Bacillus subtilis and Staphylococcus aureus) and Gram-negative bacteria (Escherichia coli and Xanthomonas malvacearum) in DMF by disc diffusion method on nutrient agar medium [16]. The sterile medium (nutrient agar medium, 15 mL) in each petri plates was uniformly smeared with cultures of Gram-positive and Gram-negative bacteria. Sterile discs of 10 mm diameter (Hi-Media) were made in each of the petri plates to which 50 μL (1 mg/mL, that is, 50 μg/disc) of the different synthesized compounds was added. The treatments also included 50 μL of DMF as negative control and streptomycin (1 mg/mL; 10 μg/disc) as positive control for comparison. For each treatment, three replicates were maintained. The plates were incubated at 37 ± 2°C for 24 h, and the size of the resulting zone of inhibition, if any, was determined.

2.4. Antifungal Activity

The synthesized compounds were screened for their antifungal activity against Fusarium oxysporum in DMF by poisoned food technique [17]. Potato dextrose agar (PDA) media were prepared, and about 15 mL of PDA was poured into each petri plate and allowed to solidify. 5 mm disc of seven-day-old culture of the test fungi was placed at the center of the petri plates and incubated at 26°C for 7 days. After incubation, the percentage inhibition was measured and three replicates were maintained for each treatment. Nystatin was used as standard. All the synthesized compounds and nystatin were tested (at the dosage of 500 μL of the compounds/petri plate, where concentration was 0.1 mg/mL) by poisoned food technique.

3. Result and Discussion

The elemental analyses data showed good agreement between the experimentally determined values and the theoretically calculated values within the limits of permissible error. Yield and substitution of the synthesized compounds are listed in Table 1.

3.1. Antibacterial Activity

The investigation of antibacterial screening data revealed that synthesized compounds showed comparable activity against Bacillus subtilis, Staphylococcus aureus, and Escherichia coli. Compound 8j exhibited good activity with the zone of inhibition in the range of 16 mm against pathogenic bacteria strain.

3.2. Antifungal Activity

The antifungal activity of synthesized compounds was evaluated and compared with standard drug nystatin. All the synthesized compounds showed moderate inhibitory activity and compound 8j showed good antifungal activity with the 56.4% inhibition against F. oxysporum, compared to other compound. Among the synthesized compounds, inhibitory activity is in the order of 8j > 8a–i > 8k against tested fungi. The compound 2a exhibited good activity against fungal strain. Antimicrobial screening results of the tested compounds are shown in Table 2.

4. Conclusion

We have demonstrated that reaction of 6-methyl-N′-(4-(pyridine-3-yl)pyrimidin-2-yl)benzene-1,3-diamine with various substituted carboxylic acid via catalyst using 1,1′-carbonyldiimidazole (CDI) resulted in new derivative of imatinib, which enables efficient synthesis in a single step with satisfactory overall yield. The products of this reaction are of potential medicinal interest. This approach has substantial advantages over previously described methods because of the ready availability of the starting materials and simple operations.

Conflict of Interests

The authors report no conflict of interests. The authors alone are responsible for the content and writing of the paper.

Acknowledgments

The authors are thankful to Professor, Dr. K. D. Patel, Chemistry Department, V.P. & R.P.T.P. Science College, Sardar Patel University, Vallabh Vidyanagar, India, for providing laboratory facilities. Central Salt & Marine Chemicals Research Institute, Bhavngar, Gujarat, India, is gratefully acknowledged.

References

X. Li, J. Yang, X. Chen et al., “A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript,” Cancer Genetics and Cytogenetics, vol. 176, no. 2, pp. 166–168, 2007.
View at: Publisher Site | Google Scholar
I. El Hajj Dib, M. Gallet, R. Mentaverri, N. Sévenet, M. Brazier, and S. Kamel, “Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity,” European Journal of Pharmacology, vol. 551, no. 1–3, pp. 27–33, 2006.
View at: Publisher Site | Google Scholar
L. C. Crossman and S. O'Brien, “Clinical results with imatinib in chronic myeloid leukaemia,” Leukemia Research, vol. 28, no. 1, pp. S3–S9, 2004.
View at: Publisher Site | Google Scholar
A. T. Van Oosterom, I. Judson, J. Verweij et al., “Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study,” The Lancet, vol. 358, no. 9291, pp. 1421–1423, 2001.
View at: Publisher Site | Google Scholar
E. Buchdunger, C. L. Cioffi, N. Law et al., “Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 139–145, 2000.
View at: Google Scholar
G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger, “The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth,” Clinical Cancer Research, vol. 6, no. 8, pp. 3319–3326, 2000.
View at: Google Scholar
A. S. Ivanov and S. V. Shishkov, “Synthesis of imatinib: a convergent approach revisited,” Monatshefte fur Chemie, vol. 140, no. 6, pp. 619–623, 2009.
View at: Publisher Site | Google Scholar
B. J. Druker and N. B. Lydon, “Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia,” Journal of Clinical Investigation, vol. 105, no. 1, pp. 3–7, 2000.
View at: Google Scholar
B. J. Druker, S. Tamura, E. Buchdunger et al., “Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells,” Nature Medicine, vol. 2, no. 5, pp. 561–566, 1996.
View at: Google Scholar
B. J. Druker, M. Talpaz, D. J. Resta et al., “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” The New England Journal of Medicine, vol. 344, no. 14, pp. 1031–1037, 2001.
View at: Publisher Site | Google Scholar
C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos et al., “Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment,” Blood, vol. 100, no. 3, pp. 1014–1018, 2002.
View at: Publisher Site | Google Scholar
A. Hochhaus, S. Kreil, A. S. Corbin et al., “Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy,” Leukemia, vol. 16, no. 11, pp. 2190–2196, 2002.
View at: Publisher Site | Google Scholar
M. E. Gorre, M. Mohammed, K. Ellwood et al., “Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification,” Science, vol. 293, no. 5531, pp. 876–880, 2001.
View at: Publisher Site | Google Scholar
J. Zimmermann, E. Buchdunger, H. Mett, T. Meyer, and N. B. Lydon, “ABL-kinase: phenylaminopyridine (PAP) derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 7, pp. 187–192, 1997.
View at: Google Scholar
H. Bredereck, F. Effenberger, and H. Bosch, “Säureamid-reaktionen, XLV. Untersuchungen über die reaktionsfähigkeit von formamidinen, dimethylformamid-diäthylacetal (Amidacetal) und Bis-dimethyl-amino-methoxy-methan (Aminalester),” Berichte der Deutschen Chemischen Gesellschaft, vol. 97, no. 12, pp. 3397–3406, 1964.
View at: Google Scholar
A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, “Antibiotic susceptibility testing by a standardized single disk method,” The American Journal of Clinical Pathology, vol. 45, no. 4, pp. 493–496, 1966.
View at: Google Scholar
S. Satish, D. C. Mohana, M. P. Raghavendra, and K. A. Raveesha, “Antifungal activity of some plant extracts against important seed borne pathogens of Aspergillus sp.,” Journal of Agricultural Technology, vol. 3, pp. 109–119, 2007.
View at: Google Scholar

Copyright

Copyright © 2013 M. J. Patoliya and G. J. Kharadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

3054

Downloads

1503

Citations